Precipitation of a poorly soluble model drug during in vitro lipolysis: Characterization and dissolution of the precipitate

Journal of Pharmaceutical Sciences

Volumn 99, Issue 12, 2010, Pages 4982-4991

  Sassene, Philip J ^a   Knopp, Matthias M ^a   Hesselkilde, Janne Z ^a   Koradia, Vishal ^a   Larsen, Anne ^a   Rades, Thomas ^b   MüLlertz, Anette ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Amorphous form; Biopharmaceutics Classification System (BCS) class 2 drugs; Cinnarizine; Digestion; Dissolution rate; in vitro lipolysis; Molecular dispersion; Polarized light microscopy (PLM); Precipitation; Self microemulsifying drug delivery system (SMEDDS); Triacylglycerides; X ray powder diffraction (XRPD)

Indexed keywords

CINNARIZINE; SODIUM HYDROXIDE;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG PELLET; DRUG SOLUBILITY; IN VITRO STUDY; LIPOLYSIS; PRECIPITATION; ULTRACENTRIFUGATION; X RAY DIFFRACTION;

EID: 78049518013     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22226     Document Type: Article

References (36)

1. Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification-The correlation of in-vitro drug product dissolution and in-vivo bioavailability. Pharm Res 12: 413-420.
2. Nielsen FS, Petersen KB, Mullertz A. 2008. Bioavailability of probucol from lipid and surfactant based formulations in minipigs: Influence of droplet size and dietary state. Eur J Pharm Biopharm 69: 553-562.
3. Pouton CW. 2000. Lipid formulations for oral administration of drugs: Non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci 11: S93-S98.
4. Humberstone AJ, Charman WN. 1997. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev 25: 103-128.
5. Shah NH, Carvajal MT, Patel CI, Infeld MH, Malick AW. 1994. Self-emulsifying drug-delivery systems (sedds) with polyglycolyzed glycerides for improving in-vitro dissolution and oral absorption of lipophilic drugs. Int J Pharm 106: 15-23.
6. Müllertz A, Ogbonna A, Ren S, Rades T. 2010. New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. J Pharmacy Pharm (in press).
7. Dai WG, Dong LC, Shi X, Nguyen J, Evans J, Xu Y, Creasey AA. 2007. Evaluation of drug precipitation of solubility-enhancing liquid formulations using milligram quantities of a new molecular entity (NME). J Pharm Sci 96: 2957-2969.
8. Mohsin K, Long MA, Pouton CW. 2009. Design of lipid-based formulations for oral administration of poorly water-soluble drugs: Precipitation of drug after dispersion of formulations in aqueous solution. J Pharm Sci 98: 3582-3595.
9. Porter CJH, Charman WN. 2001. In vitro assessment of oral lipid based formulations. Adv Drug Deliv Rev 50: S127-S147.
10. Grove M, Mullertz A, Nielsen JL, Pedersen GP. 2006. Bioavailability of seocalcitol II: Development and characterization of self-microemulsifying drug delivery systems (SMEDDS) for oral administration containing medium and long chain triglycerides. Eur J Pharm Sci 28: 233-242.
11. Godfraind T, Miller R, Wibo M. 1986. Calcium antagonism and calcium entry blockade. Pharmacol Rev 38: 321-416.
12. Singh BN. 1986. The mechanism of action of calcium antagonists relative to their clinical applications. Br J Clin Pharmacol 21: 109S-121S.
13. Towse G. 1980. Cinnarizine-A labyrinthine sedative. J Laryngol Otol 94: 1009-1015.
14. Branchu S, Rogueda PG, Plumb AP, Cook WG. 2007. A decision-support tool for the formulation of orally active, poorly soluble compounds. Eur J Pharm Sci 32: 128-139.
15. Parikh R, Parikh D, Delvadia R, Patel S. 2006. A novel multicompartment dissolution apparatus for evaluation of floating dosage form containing poorly soluble weakly basic drug. Dissolut Technol 13: 14-19.
16. Tokumura T, Tsushima Y, Tatsuishi K, Kayano M, Machida Y, Nagai T. 1987. Enhancement of the oral bioavailability of cinnarizine in oleic acid in beagle dogs. J Pharm Sci 76: 286-288.
17. Zangenberg NH, Mullertz A, Kristensen HG, Hovgaard L. 2001. A dynamic in vitro lipolysis model. II: Evaluation of the model. Eur J Pharm Sci 14: 237-244.
18. Zangenberg NH, Mullertz A, Kristensen HG, Hovgaard L. 2001. A dynamic in vitro lipolysis model. I. Controlling the rate of lipolysis by continuous addition of calcium. Eur J Pharm Sci 14: 115-122.
19. Larsen A, Ohlsson AG, Rmaileh RA, Abrahamsson B, Dickinson PA, Østergaard J, Müllertz A. 2010. Development and characterisation of self-microemulsifying drug delivery systems designed for mechanistic lipolysis studies. (in preparation).
20. Gargouri Y, Moreau H, Verger R. 1989. Gastric lipases: Biochemical and physiological studies. Biochim Biophys Acta 1006: 255-271.
21. Zentler-Munro PL, Fine DR, Fitzpatrick WJ, Northfield TC. 1984. Effect of intrajejunal acidity on lipid digestion and aqueous solubilisation of bile acids and lipids in health, using a new simple method of lipase inactivation. Gut 25: 491-499.
22. Dressman JB, Berardi RR, Dermentzoglou LC, Russell TL, Schmaltz SP, Barnett JL, Jarvenpaa KM. 1990. Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm Res 7: 756-761.
23. Carriere F, Barrowman JA, Verger R, Laugier R. 1993. Secretion and contribution to lipolysis of gastric and pancreatic lipases during a test meal in humans. Gastroenterology 105: 876-888.
24. Fatouros DG, Deen GR, Arleth L, Bergenstahl B, Nielsen FS, Pedersen JS, Mullertz A. 2007. Structural development of self nano emulsifying drug delivery systems (SNEDDS) during in vitro lipid digestion monitored by small-angle X-ray scattering. Pharm Res 24: 1844-1853.
25. Fatouros DG, Bergenstahl B, Mullertz A. 2007. Morphological observations on a lipid-based drug delivery system during in vitro digestion. Eur J Pharm Sci 31: 85-94.
26. Kleberg K, Jacobsen F, Fatouros DG, Müllertz A. 2010. Biorelevant media simulating fed state intestinal fluids: Colloid phase characterization and impact on solubilization capacity. J Pharm Sci (in press).
27. Fatouros DG, Walrand I, Bergenstahl B, Mullertz A. 2009. Colloidal structures in media simulating intestinal fed state conditions with and without lipolysis products. Pharm Res 26: 361-374.
28. Krise JP, Zygmunt J, Georg GI, Stella VJ. 1999. Novel prodrug approach for tertiary amines: Synthesis and preliminary evaluation of N-phosphonooxymethyl prodrugs. J Med Chem 42: 3094-3100.
29. Mizushima H, Fukasawa JI, Suzuki T. 1996. Phase behavior of artificial stratum corneum lipids containing a synthetic pseudo-ceramide: A study of the function of cholesterol. J Lipid Res 37: 361-367.
30. Seddon JM. 1990. Structure of the inverted hexagonal (HII) phase, and non-lamellar phase transitions of lipids. Biochim Biophys Acta 1031: 1-69.
31. Gutberlet T, Dietrich U, Klose G, Rapp G. 1998. X-ray diffraction study of the lamellar-hexagonal phase transition in phospholipid/surfactant mixtures. J Colloid Interface Sci 203: 317-327.
32. Mizushima H, Fukasawa J, Suzuki T. 1997. Intermolecular Interaction between a Synthetic Pseudoceramide and a Sterol-Combined Fatty Acid. J Colloid Interface Sci 195: 156-163.
33. Tardieu A, Luzzati V, Reman FC. 1973. Structure and polymorphism of the hydrocarbon chains of lipids: A study of lecithin-water phases. J Mol Biol 75: 711-718.
34. Luzzati V, Gulikkrz T, Tardieu A. 1968. Polymorphism of Lecithins. Nature 218: 1031-1034.
35. Corkery RW. 2004. A variation on Luzzati's soap phases. Room temperature thermotropic liquid crystals. Phys Chem Chem Phys 6: 1534-1546.
36. Hancock BC, Parks M. 2000. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 17: 397-404.